Our interest to evaluate the FASN inhibitor TCS as a potential chemotherapeutic for the treatment of PCa was supported by previous findings that TCS showed minimal toxicity in rats, dogs and baboons when treated daily over several months [22] and that knockdown or pharmacological inhibition of FASN with C75 induced cell death of PCa cells in vitro and a reduction in tumor volume in vivo (reviewed in [4]). The gene discussed is FASN; the disease is neoplasm.